The abstract is read at the publisher; the summary is JClub's.
LongPSE and ABD-longPSE enhanced tumor phagocytosis and PD-L1 stripping in macrophage-rich colorectal and pancreatic syngeneic models, outperforming magrolimab.
- Why it matters: Immunotherapies often underperform in immunologically “cold,” macrophage-rich tumor microenvironments where PD-L1–mediated immunosuppression limits effective innate and adaptive responses.
- What they did: The team engineered phagocytic synapse enhancers that fuse a high-affinity PD-L1 binder to tuftsin, then tested bridging to macrophage NRP1 and cis effects on PD-L1+ macrophages, including lead longPSE and ABD-longPSE versus magrolimab.
- The result: PSEs strengthened effector–target interactions, bypassed FcγR-dependent uptake, reprogrammed macrophages toward pro-inflammatory signaling, and remodeled lymphoid and myeloid compartments with reduced tumor-associated macrophages and regulatory T cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.